Go Pro
NASDAQ:COCP

Cocrystal Pharma Q2 2026 Earnings Report

Cocrystal Pharma logo
$1.12 -0.02 (-1.33%)
As of 10:35 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Cocrystal Pharma EPS Results

Actual EPS
-$0.23
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Cocrystal Pharma Revenue Results

Actual Revenue
$0.11 million
Expected Revenue
$0.11 million
Beat/Miss
Beat by +$5.00 thousand
YoY Revenue Growth
N/A

Cocrystal Pharma Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cocrystal Pharma's next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules.

Conference Call Resources

Cocrystal Pharma Earnings Headlines

Zacks Research Has Positive Forecast for COCP Q3 Earnings
COCP: $5 Million Private Placement with OPKO Health
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before November 3 could reprice this stock from $2 to $20 or more within a year.tc pixel
See More Cocrystal Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email.

About Cocrystal Pharma

Cocrystal Pharma (NASDAQ:COCP) (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections. Lead projects target influenza A and B polymerases as well as key enzymes in coronaviruses such as SARS-CoV-2. Additional research efforts are directed at antiviral targets in hepatitis B virus, norovirus and other emerging viral threats, reflecting Cocrystal’s commitment to addressing a broad spectrum of infectious diseases.

Founded in 2006 and headquartered in Bothell, Washington, Cocrystal Pharma leverages collaborations with academic institutions and contract research organizations to expand its drug discovery capabilities. The company maintains research laboratories in the Seattle area and operates a business development office in New York City to engage with strategic partners and investors globally.

Under the leadership of founder and Chief Executive Officer Kenneth T. Hitchcock, Ph.D., Cocrystal Pharma seeks to address unmet medical needs in antiviral therapy. By combining deep structural biology expertise with a scalable discovery engine, the company aims to advance novel antivirals poised to combat both seasonal outbreaks and future pandemic threats.

View Cocrystal Pharma Profile